Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for pain relief in end-stage metastatic castration-resistant prostate cancer
2024-513951-33-00Phase 2Authorised
- Sponsor
- Regionshospital Nordjylland
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC) comparing Cannabidiol with Placebo to cannabidiol (2 arms). Planned start Jun 2026; status: authorised.
02
Drugs
cannabidiol
03
Conditions
prostate cancer (PCa)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2024-513951-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513951-33-00.